Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiosurgery 6pembrolizumab 5Oncolytic Virotherapy 4Magnetic Resonance Spectroscopy 4Fluorodeoxyglucose F18 4Carboplatin 4Paclitaxel 3Cyclophosphamide 3Cisplatin 3osimertinib 2atezolizumab 2aldesleukin 2Tobacco Use Cessation Devices 2Specimen Handling 2Radiotherapy 2Positron-Emission Tomography 2Pemetrexed 2Nivolumab 2Docetaxel 2toripalimab 1sugemalimab 1sodium thiosulfate 1perflutren 1palbociclib 1icotinib 1gallium 68 PSMA-11 1fludarabine 1durvalumab 1dapagliflozin 1dacomitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × amatuximab × Thoracic × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡